| |
Digital transformation, AI, big data, and regulatory action—these four trends are shaping the healthcare industry. From new technologies to billion-dollar research funding, there are plenty of lucrative investment opportunities to be had. Learn more.
|
|
Today’s Big NewsAug 25, 2023 |
|
October 16-17 | Boston, MA
Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book your seat today and save $200!
|
|
| By Fraiser Kansteiner In a phase 3 study, semaglutide at the 2.4 mg dose bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction. The drug also led to greater improvements in exercise function and more weight loss versus a dummy drug, according to study results published in The New England Journal of Medicine Friday. |
|
|
|
By James Waldron RayzeBio has already persuaded investors to hand over more than $400 million to pursue its targeted radiation approach to treating cancer. Now, with its lead product in phase 3 trials, the biotech is eyeing up an IPO to push its plans forward. |
By Conor Hale To simply describe it as an upgrade over the traditional ice-packed, off-the-shelf cooler is an understatement. |
By Angus Liu Add another failed trial to the list of setbacks for Merck and Eisai’s combination of Keytruda and Lenvima. The companies have decided to shut down a phase 3 study testing the PD-1/TKI combo in first-line head and neck cancer. |
By Nick Paul Taylor Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will follow patients for around six years. |
By Zoey Becker The company cited concerns with the law's consequences for orphan drug development. AstraZeneca becomes the sixth drugmaker to file suit against the IRA. |
By Helen Floersh With the help of advanced algorithms and DNA sequencing techniques, scientists have decoded the Y chromosome in full for the first time. |
By Andrea Park Theken Companies, an Ohio-based family of medical implant makers, has found the next member of its family within the Buckeye State. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
